Clinical trial · no report yet · Phase 2
NCT05132777
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
- NCT05132777 ↗
- Unknown
- Shanghai JMT-Bio Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations
- Interventions
- JMT101; Osimertinib Mesylate Tablets
- Arms
- JMT101 in combination with Osimertinib · Experimental
- Enrollment
- 155 (estimated)
- Primary outcomes
- Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1
- Sponsor
- Shanghai JMT-Bio Inc. with CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Start
- Nov 20, 2021 (estimated)
- Primary completion
- Sep 30, 2023 (estimated)
- Results posted
- No
- Registry record
- NCT05132777 · updated Nov 24, 2021